Valion Bio, Inc. 8-K

What Happened
Valion Bio, Inc. (VBIO) filed a Current Report on Form 8‑K dated May 14, 2026 reporting its results of operations and financial condition. The filing includes a Regulation FD disclosure and incorporates the information by reference into the Form 8‑K. A press release providing the disclosed information was furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 14, 2026 (Form 8‑K filed with the SEC).
• Reported items: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
• Exhibits: 99.1 — Press Release dated May 14, 2026; 104 — Cover Page Interactive Data File (Inline XBRL).
• The press release attached to the 8‑K contains the detailed disclosure of the company’s operational/financial results (see Exhibit 99.1 for specifics).

Why It Matters
This 8‑K signals that Valion Bio has publicly disclosed recent operational and financial information that could affect the company’s stock and investor decisions. Retail investors should review the attached press release (Exhibit 99.1) and the Inline XBRL data (Exhibit 104) for the specific earnings, revenue, or balance sheet details referenced in Item 2.02. The Regulation FD disclosure indicates the company made material information publicly available in accordance with fair disclosure rules.